Opiod Dependence Pipeline Report builds understanding of the Limitations and challenges with regard to the development of Opiod Dependence

 Breaking News
  • No posts were found

Opiod Dependence Pipeline Report builds understanding of the Limitations and challenges with regard to the development of Opiod Dependence

Opiod Dependence Pipeline Report builds understanding of the Limitations and challenges with regard to the development of Opiod Dependence

DelveInsight’s, “Opioid Dependence Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Opioid Dependence pipeline landscape. It covers the Opiod Dependence pipeline drug profiles, including Opiod Dependence clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Opiod Dependence Emerging drugs, the Opiod Dependence pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Opiod Dependence pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Opiod Dependence Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Opiod Dependence clinical trials studies, Opiod Dependence NDA approvals (if any), and product development activities comprising the technology, Opiod Dependence collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Opiod Dependence Pipeline Report

 

  • DelveInsight’s Opiod Dependence pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Opiod Dependence treatment.

 

  • The leadingOpiod Dependence Companies includes Sen Jam Pharmaceutical, Mindmed, Emergent BioSolutions, Opiant Pharmaceuticals, ATAI Life Sciences, Aphios, Inventage Lab Inc.,  Trevena Inc., Foresee Pharmaceuticals Co., Ltd, DemeRx, AphioTx Inc., Lyndra Therapeutics, AstraZeneca, Orexo AB, Alar Pharmaceuticals, Ensysce biosciences, Gilgamesh Pharmaceuticals, Indivior, Cerevel Therapeutics, BioCorRx, Kinoxis Therapeutics, Aptinyx, and others.

 

  • Promising Opiod Dependence Pipeline Therapies includes SJP 006, SJP 007, Zolunicant, Naloxone multidose nasal spray, Cannabidiol, Intranasal nalmefene, Morphine extended release, KUR 101, C4X 3256, APH-1501, IVL3004, TRV734, DMX-1002, FP-004, DMX-NB1, DMX-IB1, LYN-014, LYN-013, AZD4041, OX124, OX125, ALA-1000, ALA-1300, ALA-2000, GM-300X, SBS-226, CVL-354, BICX104, KNX100, NYX-783, and others.

 

  • The Opiod Dependence pipeline companies and academics are working to assess challenges and seek opportunities that could influence R&D Opioid Dependence. The Opiod Dependence pipeline therapies under development are focused on novel approaches to treat/improve Opioid Dependence.

 

Request a sample and discover the recent breakthroughs happening in the Opiod Dependence Pipeline landscape @ Opiod Dependence Pipeline Outlook Report

 

Opiod Dependence Overview

Opioid use disorder is the chronic use of opioids that causes clinically significant distress or impairment. Opioid use disorders affect over 16 million people worldwide, over 2.1 million in the United States, and there are over 120,000 deaths worldwide annually attributed to opioids. There are as many patients using opioids regularly as there are patients diagnosed with obsessive-compulsive disorder, psoriatic arthritis, and epilepsy in the United States.

 

Recent Developmental Activities in the Opiod Dependence Treatment Landscape

 

  • In December 2022, the US Food and Drug Administration (FDA) accepted the resubmitted New Drug Application (NDA) for Brixadi (buprenorphine) extended-release weekly and monthly subcutaneous injection for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.

 

  • Through a collaboration with the National Institute on Drug Abuse (NIDA), Trevena is developing TRV734 for use in medication-assisted therapy for the treatment of opioid use disorder. Similar to current standard treatment options, it targets the mu receptor, but with an optimized mechanism of action that preferentially engages the signaling pathway responsible for therapeutic effect, with reduced activation of the signaling pathway responsible for mu receptor-mediated adverse effects.

 

  • LYN-014, Lyndra’s investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD). The capsule is expected to achieve this through a novel design that will provide extended gastric residence, controlled, steady drug release and timely passage into the gastrointestinal tract. In July 2021, LYN-014 received Fast Track designation (FTD) from the US Food and Drug Administration (FDA).

 

  • In November 2022, Aptinyx Inc. announced the finalization of a grant, issued to researchers at Yale University School of Medicine, funding the research and development of NYX-783 for the treatment of OUD. The $5.6 million grant was awarded under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, administered by the National Institute on Drug Abuse (NIDA). The first clinical study funded by the grant will be a randomized, double-blind, placebo-controlled, Phase I drug-drug interaction study to assess the safety, tolerability, and pharmacokinetics of NYX-783 in combination with oxycodone in individuals who use opioids.

  

For further information, refer to the detailed Opiod Dependence Drugs Launch, Opiod Dependence Developmental Activities, and Opiod Dependence News, click here for Opiod Dependence Ongoing Clinical Trial Analysis

 

Opiod Dependence Emerging Drugs Profile

 

  • Zolunicant:  MindMed

Zolunicant (MM-110) is a α3β4 nicotinic cholinergic receptor antagonist that offers a novel mechanism to address a critical gap in current opioid use disorder treatment. Positive safety and tolerability results support the advancement of MM-110 and guide the Phase IIa dose design in individuals undergoing supervised opioid withdrawal. Phase IIa trial remains on track to initiate in Q2 2022.

 

  • KUR-101: ATAI Life Sciences

KUR-101, is a derivative of mitragynine, the major active alkaloid of the kratom plant. KUR-101 is atypical opioid receptor modulators, boasting unique pharmacology that may make them safer than currently available opioids in treating pain.

 

Opiod Dependence Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies Opioid Dependence. The companies which have their Opioid Dependence drug candidates in the most advanced stage, i.e phase III include Opiant Pharmaceuticals

 

Find out more about the Opiod Dependence Pipeline Segmentation, Therapeutics Assessment, and Opiod Dependence Emerging Drugs @ Opiod Dependence Treatment Landscape

 

Scope of the Opiod Dependence Pipeline Report

 

  • Coverage- Global

 

  • Opiod Dependence Companies- Medicenna Therapeutics, Tarveda Therapeutics, Sen Jam Pharmaceutical, Mindmed, Emergent BioSolutions, GW Pharmaceuticals, Opiant Pharmaceuticals, ATAI Life Sciences, C4X Discovery,  and others

 

  • Opiod Dependence Pipeline Therapies- SJP 006, SJP 007, Zolunicant, Naloxone multidose nasal spray, Cannabidiol, Intranasal nalmefene, Morphine extended release, KUR 101, C4X 3256, and others.

 

  • Opiod Dependence Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Opiod Dependence Pipeline Companies and Therapies, click here @ Opiod Dependence Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Opioid Dependence: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Opioid Dependence– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Intranasal nalmefene: Opiant Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Drug name: Company name
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Zolunicant: Mindmed
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Preclinical)
  17. Sen Jam Pharmaceutical: SJP 007
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Opioid Dependence Key Companies
  21. Opioid Dependence Key Products
  22. Opioid Dependence- Unmet Needs
  23. Opioid Dependence- Market Drivers and Barriers
  24. Opioid Dependence- Future Perspectives and Conclusion
  25. Opioid Dependence Analyst Views
  26. Opioid Dependence Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Opiod Dependence Mergers and acquisitions, Opiod Dependence Licensing Activities @ Opiod Dependence Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories